AIM Vaccine submitted the pre-application for clinical trials for novel-process highly-effective human diploid rabies vaccine
Achieve quality upgrade of traditional human diploid wild seedlings HONG KONG SAR - Media OutReach Newswire - 27 March 2024 - AIM Vaccine Co., Ltd. (the "AIM Vaccine", together with its subsidiaries, the "Group") is pleased to announce that the Group has submitted the pre-application for clinical trials for novel-process highly-effective human diploid rabies vaccine on March 24
read full article
